Japan Establishes Global Trust and Safety in Stem Cell Therapy Through Rigorous Act on the Safety of Regenerative Medicine (ASRM)

August 30, 2026

Grand Green Osaka Umekita Clinic Japan

Overview

Japan has solidified its position as a globally trusted nation for regenerative medicine, including stem cell therapy, through the 2014 Act on the Safety of Regenerative Medicine (ASRM). This law mandates that all medical institutions submit detailed treatment plans to the Ministry of Health, Labour and Welfare (MHLW) for approval, ensuring a rigorous framework for enhanced safety and transparency in stem cell treatments. This legislative foresight has made Japan a benchmark for ethical and safe clinical application of advanced cell therapies.

In Depth

Key Findings

Through the enactment of the ‘Act on the Safety of Regenerative Medicine (ASRM)’ in 2014, Japan has globally established its reputation as a trusted nation for providing regenerative medicine, including advanced stem cell therapies, characterized by high safety standards and transparency. This landmark legislation mandates that all medical institutions intending to offer regenerative medicine treatments must submit detailed treatment plans to the Ministry of Health, Labour and Welfare (MHLW) for rigorous review and approval. This framework ensures a robust regulatory environment that prioritizes patient safety above all else, making Japan recognized worldwide as a reliable destination for receiving stem cell therapies.

Technical & Clinical Details

The ASRM Act categorizes the provision of regenerative medicine into ‘manufacturing and use of specific processed cells’ and ‘provision of regenerative medicine, etc.,’ establishing corresponding licensing and notification systems. For instance, medical institutions offering therapies utilizing mesenchymal stem cells (MSCs) or exosome therapies are required to submit comprehensive information to the MHLW. This includes the type of cells used, manufacturing methods, administration routes, therapeutic objectives, target diseases, and anticipated benefits and risks. The MHLW rigorously evaluates these plans based on scientific validity, safety, and ethical considerations. Only approved treatment plans are permitted for implementation, and post-treatment, mandatory reporting of adverse events and regular safety evaluations are enforced. This ensures that all provided stem cell therapies maintain the highest standards of quality and safety throughout their application and monitoring.

Background & Industry Context

Regenerative medicine, particularly stem cell therapy, has faced regulatory challenges globally due to its immense potential. Instances of unapproved or poorly substantiated treatments posing risks to patient safety have been observed worldwide. In response to this landscape, and catalyzed by the Nobel Prize awarded for iPSC research in 2012, Japan developed a unique regulatory model aiming to balance scientific advancement with patient safety. The ASRM Act introduces a flexible approach distinct from the existing Pharmaceuticals and Medical Devices Act (PMDAct), striving to achieve both rapid practical application of therapies and assurance of safety. This Japanese regulatory model has garnered significant international attention and serves as a reference for other countries developing their own regenerative medicine regulations.

Strategic Significance & Outlook

Japan’s stringent regulatory environment under the ASRM Act will continue to guarantee the safety of stem cell therapies and foster further technological innovation. As international patient trust grows, Japan is expected to strengthen its position as a global hub for stem cell treatments. Concurrently, regulatory authorities must continuously adapt through flexible implementation and necessary revisions of the law to accommodate the emergence of new cell therapy modalities and advancements in manufacturing technologies. Within this supportive framework, Japanese stem cell clinics are anticipated to further expand their offerings of advanced therapies for conditions such as anti-aging, osteoarthritis, and diabetes, all delivered from GMP-compliant laboratories, reinforcing Japan’s leadership in this cutting-edge medical field.

Source: https://umekitaclinic.org/cell-therapy/stem-cell/en/blog/12458/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.